NKGEN BIOTECH
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 63
- Market Cap
- -
- Website
- http://www.nkgenbiotech.com
- Introduction
NKGen Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development and commercialization of innovative autologous, allogeneic, and CAR-NK cell therapies utilizing a proprietary SNK platform. Its product candidates are based on a proprietary manufacturing and cryopreservation process which produces SNK cells that have high potency as defined by parameters such as cytotoxicity, cytokine production, and activating receptor expression. The company was founded by Sangwoo Park in 2017 and is headquartered in Santa Ana, CA.
Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- NKGen Biotech, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06189963
- Locations
- 🇺🇸
Valiance Clinical Research, Tarzana, California, United States
🇺🇸Syrentis Clinical Research, Santa Ana, California, United States
🇺🇸Behavioral Research Specialists, LLC, Glendale, California, United States
Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- NKGen Biotech, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05990920
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸Angeles Clinic and Research Institute, Los Angeles, California, United States
Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- NKGen Biotech, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT05099549
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD)
- Conditions
- Interventions
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- NKGen Biotech, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04678453
- Locations
- 🇲🇽
Hospital Angeles Tijuana, Tijuana, Baja California, Mexico
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
- Conditions
- Interventions
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- NKGen Biotech, Inc.
- Registration Number
- NCT04464967
Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy
- First Posted Date
- 2019-05-07
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- NKGen Biotech, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT03941262
- Locations
- 🇺🇸
Sarcoma Oncology Research Center, Santa Monica, California, United States
Autologous Natural Killer Cells in Subjects With Plaque Psoriasis
- Conditions
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2020-06-26
- Lead Sponsor
- NKGen Biotech, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT03894579
- Locations
- 🇲🇽
Hospital Angeles, Tijuana, BC, Mexico